---
layout: default
title: Fenoprofen
description: "Fenoprofen çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 71
evidence_level: L5
indication_count: 10
---

# Fenoprofen

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Fenoprofen è—¥å¸«è©•ä¼°ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Fenoprofen å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Fenoprofen æ˜¯ä¸€ç¨® NSAID é¡æ­¢ç—›è—¥ï¼ŒTxGNN é æ¸¬å…¶å¯ç”¨æ–¼å¤šç¨®éª¨éª¼è‚Œè‚‰ç–¾ç—…ï¼Œå…¶ä¸­åƒµç›´æ€§è„Šæ¤ç‚çš„é æ¸¬å…·æœ‰å¤šé …è‡¨åºŠè©¦é©—æ”¯æŒã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Fenoprofen (èŠ¬è«¾æ™®èŠ¬) |
| DrugBank ID | DB00573 |
| å°ç£å•†å“å | é¢¨è«¾ä¿è† å›Š |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | é¢¨æ¿•æ€§é—œç¯€ç‚ã€éª¨é—œç¯€ç‚ã€æ€¥æ€§ç—›é¢¨ã€é®ç—›ã€è§£ç†± |
| é æ¸¬æ–°é©æ‡‰ç—‡ | osteoarthritis susceptibilityã€osteoarthritisã€rheumatoid arthritisã€acromesomelic dysplasia, Hunter-Thompson typeã€brachyolmia-amelogenesis imperfecta syndromeã€myosclerosisã€brachyolmiaã€brachydactyly-syndactyly syndromeã€colobomatous microphthalmia-rhizomelic dysplasia syndromeã€arthropathy |
| æœ€é«˜é æ¸¬åˆ†æ•¸ | 0.9999 (acromesomelic dysplasia) |
| è­‰æ“šç­‰ç´š | L2 (åƒµç›´æ€§è„Šæ¤ç‚æœ‰å¤šå€‹è‡¨åºŠè©¦é©—) |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†

Fenoprofen ä½œç‚ºä¸™é…¸é¡ NSAIDï¼Œå…¶å°é æ¸¬é©æ‡‰ç—‡çš„æ©Ÿè½‰å¦‚ä¸‹ï¼š

1. **COX æŠ‘åˆ¶ä½œç”¨**ï¼šåŒæ™‚æŠ‘åˆ¶ COX-1 å’Œ COX-2ï¼Œæ¸›å°‘å‰åˆ—è…ºç´ åˆæˆ
2. **æŠ—ç™¼ç‚æ•ˆæœ**ï¼šå°é—œç¯€ç‚å’Œè„Šæ¤ç‚çš„ç™¼ç‚æœ‰æ•ˆ
3. **æ­¢ç—›ä½œç”¨**ï¼šä¸­æ¨å’Œå‘¨é‚Šçš„æ­¢ç—›æ©Ÿè½‰
4. **åŒé¡è—¥ç‰©æ¯”è¼ƒ**ï¼šå±¬æ–¼èˆ‡ naproxenã€ibuprofen åŒé¡çš„ä¸™é…¸é¡ NSAID

### åƒµç›´æ€§è„Šæ¤ç‚é æ¸¬ç‰¹åˆ¥åˆç†
- NSAIDs æ˜¯åƒµç›´æ€§è„Šæ¤ç‚çš„ä¸€ç·šæ²»ç™‚è—¥ç‰©
- éƒ¨åˆ†åŸæ ¸å‡†é©æ‡‰ç—‡å·²åŒ…å«ã€Œé—œç¯€å¼·ç¡¬æ€§è„Šæ¤ç‚ã€ï¼ˆå³åƒµç›´æ€§è„Šæ¤ç‚ï¼‰

## è‡¨åºŠè©¦é©—è­‰æ“š

### åƒµç›´æ€§è„Šæ¤ç‚ç›¸é—œè©¦é©—

é›–ç„¶ ClinicalTrials.gov æœªæ‰¾åˆ°è¿‘æœŸè©¦é©—ï¼Œä½† PubMed æ–‡ç»è¨˜è¼‰äº†å¤šé …æ­·å²è‡¨åºŠè©¦é©—ï¼š

| ç ”ç©¶ | è¨­è¨ˆ | é—œéµç™¼ç¾ |
|------|------|---------|
| Wordsworth 1980 | é›™ç›²äº¤å‰è©¦é©— | Fenoprofen 600mg tid vs Phenylbutazone 100mg tidï¼›Phenylbutazone è¼ƒå„ª |
| Wasner 1981 | é›™ç›²éš¨æ©Ÿè©¦é©— | æ¯”è¼ƒ 6 ç¨® NSAIDsï¼Œfenoprofen ç‚ºåƒµç›´æ€§è„Šæ¤ç‚çš„æœ‰æ•ˆé¸æ“‡ä¹‹ä¸€ |
| Shipley 1980 | é›™ç›²äº¤å‰è©¦é©— | Fenoprofen vs Indomethacin vs å®‰æ…°åŠ‘æ¯”è¼ƒ |

**è­‰æ“šç­‰ç´šï¼šL2 (å¤šå€‹è‡¨åºŠè©¦é©—)**

## æ–‡ç»è­‰æ“š

### åƒµç›´æ€§è„Šæ¤ç‚

| PMID | å¹´ä»½ | ç ”ç©¶é¡å‹ | é—œéµç™¼ç¾ |
|------|------|----------|---------|
| 7010512 | 1980 | RCT | 30 ä½æ‚£è€…ï¼›fenoprofen æ”¹å–„èƒ¸å»“æ“´å¼µï¼Œä½†æ•´é«”æ•ˆæœä¸å¦‚ phenylbutazone |
| 7026817 | 1981 | RCT | 32 ä½æ‚£è€…ï¼›naproxenã€indomethacinã€fenoprofen ç‚ºæœ€æœ‰æ•ˆçš„ä¸‰ç¨® NSAIDs |
| 6996071 | 1980 | RCT | Fenoprofen å„ªæ–¼å®‰æ…°åŠ‘ï¼Œä½†ä¸å¦‚ indomethacin |
| 324748 | 1977 | ç¶œè¿° | Fenoprofen 2.4g/day ç”¨æ–¼åƒµç›´æ€§è„Šæ¤ç‚çš„ç™‚æ•ˆèˆ‡å®‰å…¨æ€§å›é¡§ |

### å…¶ä»–é—œç¯€ç–¾ç—…

| PMID | å¹´ä»½ | ç ”ç©¶é¡å‹ | é—œéµç™¼ç¾ |
|------|------|----------|---------|
| 387372 | 1979 | ç¶œè¿° | æ¯”è¼ƒ naproxen å’Œ fenoprofen åœ¨é¡é¢¨æ¿•æ€§é—œç¯€ç‚çš„æ•ˆæœ |
| 300118 | 1977 | ç¶œè¿° | Fenoprofenã€naproxenã€tolmetin åœ¨é¢¨æ¿•ç–¾ç—…çš„æ‡‰ç”¨ |

### é‡è¦æ­·å²ç ”ç©¶
Brogden et al. (1977) çš„è—¥ç‰©å›é¡§æŒ‡å‡ºï¼š
- Fenoprofen 2.4g/day ç™‚æ•ˆèˆ‡ aspirin 3.6-4g/day ç›¸ç•¶
- èƒƒè…¸é“å‰¯ä½œç”¨è¼ƒ aspirin å°‘ä¸”è¼•å¾®
- å¯ç”¨æ–¼é¡é¢¨æ¿•æ€§é—œç¯€ç‚ã€é€€åŒ–æ€§é—œç¯€ç‚ã€åƒµç›´æ€§è„Šæ¤ç‚å’Œç—›é¢¨

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰å­—è™Ÿ | ä¸­æ–‡å“å | åŠ‘é‡ | è¨±å¯è­‰æŒæœ‰è€… | ç‹€æ…‹ |
|-----------|---------|------|-------------|------|
| è¡›ç½²è—¥è£½å­—ç¬¬041435è™Ÿ | æ‡‰å…ƒç‚æ™®æœ—è† å›Š | 200mg | æ‡‰å…ƒåŒ–å­¸è£½è—¥ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬037862è™Ÿ | ä¼ç‚ç—›è† å›Š | - | è¥¿å¾·æœ‰æ©ŸåŒ–å­¸è—¥å“ | æœ‰æ•ˆ |
| è¡›ç½²è—¥è£½å­—ç¬¬011765è™Ÿ | é¢¨è«¾ä¿è† å›Š | 300mg | è‡ºç£ç¦®ä¾† | å·²è¨»éŠ· |

**æ³¨æ„**ï¼šå¤šæ•¸ fenoprofen è£½åŠ‘å·²è¨»éŠ·ï¼Œç›®å‰åœ¨å°ç£å–å¾—è¼ƒå›°é›£ã€‚

## å®‰å…¨æ€§è€ƒé‡

### å·²çŸ¥é¢¨éšª
- **èƒƒè…¸é“é¢¨éšª**ï¼šæ½°ç˜ã€å‡ºè¡€ã€ç©¿å­”
- **å¿ƒè¡€ç®¡é¢¨éšª**ï¼šNSAIDs é¡æ•ˆæ‡‰ï¼Œå¯èƒ½å¢åŠ å¿ƒè¡€ç®¡äº‹ä»¶é¢¨éšª
- **è…è‡Ÿé¢¨éšª**ï¼šå¯èƒ½å°è‡´æ€¥æ€§è…æå‚·ï¼Œå°¤å…¶åœ¨è„«æ°´ç‹€æ…‹
- **éæ•åæ‡‰**ï¼šaspirin éæ•è€…å¯èƒ½äº¤å‰éæ•

### è—¥ç‰©äº¤äº’ä½œç”¨

æ ¹æ“š DDInter è³‡æ–™åº«ï¼š

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡åº¦ | èªªæ˜ |
|-------------|--------|------|
| Acetylsalicylic acid | Moderate | å¢åŠ èƒƒè…¸é“å‡ºè¡€é¢¨éšª |
| Hydrocortisone | Moderate | å¢åŠ èƒƒè…¸é“å‰¯ä½œç”¨ |
| Metformin | Moderate | å¯èƒ½å¢åŠ ä¹³é…¸ä¸­æ¯’é¢¨éšª |
| Triamcinolone | Moderate | å¢åŠ èƒƒè…¸é“å‰¯ä½œç”¨ |
| Famotidine | Minor | å¯é™ä½ NSAIDs ç›¸é—œæ½°ç˜é¢¨éšª |
| Ranitidine | Minor | å¯é™ä½ NSAIDs ç›¸é—œæ½°ç˜é¢¨éšª |

### ç¦å¿Œç—‡
- æ´»å‹•æ€§èƒƒè…¸é“æ½°ç˜æˆ–å‡ºè¡€
- åš´é‡å¿ƒè¡°ç«­
- å† ç‹€å‹•è„ˆç¹é“æ‰‹è¡“å‰å¾Œ
- å° NSAIDs æˆ– aspirin éæ•

### ç‰¹æ®Šæ—ç¾¤
- **å­•å©¦**ï¼šC ç´š(ç¬¬ä¸‰å­•æœŸ D ç´š)ï¼Œé¿å…ä½¿ç”¨
- **å“ºä¹³**ï¼šåˆ†æ³Œè‡³ä¹³æ±ï¼Œä¸å»ºè­°ä½¿ç”¨
- **è€å¹´äºº**ï¼šå¢åŠ èƒƒè…¸é“å‡ºè¡€é¢¨éšªï¼Œå»ºè­°æœ€ä½æœ‰æ•ˆåŠ‘é‡
- **è…åŠŸèƒ½ä¸å…¨**ï¼šé¿å…ä½¿ç”¨æˆ–æ¸›é‡

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šThe concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as...
- å»ºè­°ï¼šPatients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Anemia** ğŸŸ¡ Moderate
- Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be ...

**å¿ƒè‡Ÿè¡°ç«­ (Heart Failure)** ğŸŸ¡ Moderate
- Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are exp...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevati...

**Hyperkalemia** ğŸŸ¡ Moderate
- Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects h...

**é«˜è¡€å£“ (Hypertension)** ğŸŸ¡ Moderate
- Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be u...

*å¦æœ‰ 7 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### æ•´é«”è©•ä¼°
åƒµç›´æ€§è„Šæ¤ç‚çš„é æ¸¬**å…·æœ‰è‡¨åºŠåƒ¹å€¼**ï¼ŒåŸå› å¦‚ä¸‹ï¼š
1. å¤šå€‹æ­·å² RCT æ”¯æŒ fenoprofen å°åƒµç›´æ€§è„Šæ¤ç‚çš„ç™‚æ•ˆ
2. NSAIDs æ˜¯åƒµç›´æ€§è„Šæ¤ç‚çš„ä¸€ç·šæ²»ç™‚è—¥ç‰©
3. éƒ¨åˆ†åŸæ ¸å‡†é©æ‡‰ç—‡å·²æ¶µè“‹æ­¤ç”¨é€”

å…¶ä»–é æ¸¬ï¼ˆå¦‚ç½•è¦‹éª¨éª¼ç™¼è‚²ç•°å¸¸ï¼‰ç¼ºä¹è­‰æ“šï¼Œä¸å»ºè­°æ‡‰ç”¨ã€‚

### å»ºè­°è¡Œå‹•
- [x] åƒµç›´æ€§è„Šæ¤ç‚å¯ä½œç‚º fenoprofen çš„åˆç†ä½¿ç”¨é©æ‡‰ç—‡
- [ ] è€ƒé‡åˆ° fenoprofen åœ¨å°ç£å–å¾—å›°é›£ï¼Œå¯å„ªå…ˆé¸ç”¨å…¶ä»–åŒé¡ NSAIDs
- [ ] å…¶ä»–é æ¸¬çš„ç½•è¦‹ç–¾ç—…éœ€è¦é€²ä¸€æ­¥ç ”ç©¶

### è‡¨åºŠå»ºè­°
å°æ–¼åƒµç›´æ€§è„Šæ¤ç‚æ‚£è€…ï¼š
1. NSAIDs ä»æ˜¯ä¸€ç·šè—¥ç‰©é¸æ“‡
2. Fenoprofen æ˜¯æœ‰æ•ˆé¸é …ä¹‹ä¸€ï¼Œä½†ç™‚æ•ˆå¯èƒ½ä¸å¦‚ indomethacin æˆ– naproxen
3. è‹¥ fenoprofen ä¸å¯å¾—ï¼Œå¯é¸ç”¨å…¶ä»–ä¸™é…¸é¡ NSAIDs

### é¢¨éšªç­‰ç´š
**ä¸­ç­‰é¢¨éšª** - åƒµç›´æ€§è„Šæ¤ç‚ä½¿ç”¨æœ‰è­‰æ“šæ”¯æŒï¼Œä½†éœ€æ³¨æ„ NSAIDs é€šç”¨é¢¨éšª

---

*å ±å‘Šç”Ÿæˆæ—¥æœŸï¼š2026-02-11*
*è³‡æ–™ä¾†æºï¼šTxGNN é æ¸¬ã€ClinicalTrials.govã€PubMedã€TFDA*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Dipyridamole]({{ "/drugs/dipyridamole/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Travoprost]({{ "/drugs/travoprost/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Pemetrexed]({{ "/drugs/pemetrexed/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Polysorbate 80]({{ "/drugs/polysorbate_80/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ferrous Gluconate]({{ "/drugs/ferrous_gluconate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Fenoprofenè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/fenoprofen/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_fenoprofen,
  title = {Fenoprofenè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/fenoprofen/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
